Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway

Abstract

Survivin is an inhibitor of apoptosis protein, which is over-expressed in most tumors. Aberrant expression of survivin and loss of wild-type p53 in many tumors prompted us to investigate a possible link between these two events. Here we show that wild-type p53 represses survivin expression at both mRNA and protein levels. Transient transfection analyses revealed that the expression of wild-type p53, but not mutant p53, was associated with strong repression of the survivin promoter in various cell types. The over-expression of exogenous survivin protein rescues cells from p53-induced apoptosis in a dose-dependent manner, suggesting that loss of survivin mediates, at least, in part the p53-dependent apoptotic pathway. In spite of the presence of two putative p53-binding sites in the survivin promoter, deletion and mutation analyses suggested that neither site is required for transcriptional repression of survivin expression. This was confirmed by chromatin immunoprecipitation assays. Further analyses suggested that the modification of chromatin within the survivin promoter could be a molecular explanation for silencing of survivin gene transcription by p53.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

Abbreviations

IAP:

inhibitor of apoptosis protein

rAd-p53:

recombinant adenovirus encoding wild-type p53

rAd-control:

recombinant adenovirus containing empty vector

HDAC:

histone deacetylase complex

ChIP:

chromatin immunoprecipitation

PCNA:

proliferating cell nuclear antigen

TSA:

trichostatin A

References

  • Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri D . 1998 Lancet 351: 882–883

  • Ambrosini G, Adida C, Altieri DC . 1997 Nat. Med. 3: 917–921

  • Asker C, Wiman KG, Selivanova G . 1999 Biochem. Biophys. Res. Commun. 265: 1–6

  • Bargonetti J, Chicas A, White D, Prives C . 1997 Cell. Mol. Biol. 43: 935–949

  • Bates S, Vousden KH . 1999 CMLS Cell. Mol. Life Sci. 55: 28–37

  • Borellin F, Glazer R . 1993 J. Biol. Chem. 268: 7923–7928

  • Brownell JE, Allis CD . 1996 Curr. Opin. Genet. Dev. 6: 176–184

  • Budhram-Mahadeo V, Morris PJ, Smith MD, Midgley CA, Boxer LM, Latchman DS . 1999 J. Biol. Chem. 274: 15237–15244

  • Chen J, Wu W, Tahir SK, Kroeger PE, Rosenberg SH, Cowsert LM, Bennett F, Krajewski S, Krajewska M, Welsh K, Reed JC, Ng S-C . 2000 Neoplasia 2: 235–241

  • Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ . 1979 Biochemistry 18: 5294–5299

  • Eberhardy SR, D'Cunha CA, Farnham PJ . 2000 J. Biol. Chem. 275: 33798–33805

  • El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B . 1992 Nat. Genet. 1: 45–49

  • Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B . 2001 Genes Dev. 15: 2069–2082

  • Grossman D, McNiff JM, Li F, Altieri DC . 1999 J. Inverst. Dermatol. 113: 1076–1081

  • Grossman D, Kim PJ, Blanc-Brude OP, Brash DE, Tognin S, Marchisio PC, Altieri DC . 2001 J. Clinical Inverst. 108: 991–999

  • Hirose S . 1998 J. Biochem. 124: 1060–1064

  • Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M . 2002 J. Biol. Chem. 277: 3247–3257

  • Kawasaki H, Altieri DC, Lu C-D, Toyoda M, Tenjo T, Tanigawa N . 1998 Cancer Res. 58: 5071–5074

  • Kiermaier A, Eilers M . 1997 Curr. Biol. 7: R505–R507

  • Lee KC, Crowe AJ, Barton MC . 1999 Mol. Cell. Biol. 19: 1279–1288

  • Li F, Ambrosin G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altier DC . 1998 Nature 396: 580–584

  • Li F, Altieri DC . 1999 Biochem. J. 344: 305–311

  • Lu C-D, Altieri DC, Tanigawa N . 1998 Cancer Res. 58: 1808–1812

  • Martin DW, Munoz RM, Subler MA, Deb S . 1993 J. Biol. Chem. 268: 13062–13067

  • Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, Martin C, Font A, Barnadas A, Abad A . 1999 J. Clin. Oncol. 17: 2100–2104

  • Morris GF, Bischoff JR, Mathews MB . 1996 Proc. Natl. Acad. Sci. USA 93: 895–899

  • Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, George DL . 1999 Genes Dev. 13: 2490–2501

  • Olie RA, Simoes-Wust P, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangmeister-Wittke U . 2000 Cancer Res. 60: 2805–2809

  • Ori A, Zauberman A, Doitsh G, Paran N, Oren M, Shaul Y . 1998 EMBO J. 17: 544–553

  • Pazin MJ, Kadonaga J . 1997 Cell 89: 325–328

  • Sabbatini P, Chio S-K, Rao L, White E . 1995 Mol. Cell. Biol. 15: 1060–1070

  • Santoso JT, Tang D-C, Lane SB, Hung J, Reed DJ, Muller CY, Carbone DP, Lucci III JA, Miller DS, Mathis JM . 1995 Gynecol. Oncol. 59: 171–178

  • Seto E, Usheva A, Zambetti GP, Momand J, Horikoshi N, Weinmann R, Levine AJ, Shenk T . 1992 Proc. Natl. Acad. Sci. USA 89: 12028–12032

  • Shin S, Sung B-J, Cho Y-S, Kim H-J, Ha N-C, Hwang J-I, Chung C-W, Jung Y-K, Oh B-H . 2001 Biochemistry 40: 1117–1123

  • Sionov RV, Haupt Y . 1999 Oncogene 18: 6145–6157

  • Somasundaram K, El-Deiry WS . 2000 Frontiers in Bioscience 5: 424–437

  • Takahashi Y, Rayman JB, Dynlacht BD . 2000 Genes Dev. 14: 804–816,

  • Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC . 1998 Cancer Res. 58: 5315–5230

  • Vogelstein B, Lane D, Levine AJ . 2000 Nature 408: 307–310

  • Wang L, Wu Q, Qiu P, Mirza A, McGuirk M, Kirschmeier P, Greene JR, Wang Y, Pickett CB, Liu S . 2001 J. Biol. Chem. 276: 43604–43610

  • Wen SF, Xie L, McDonald M, DiGiacomo R, Chang A, Gurnani M, Shi B, Liu S, Indelicato SR, Hutchins B, Nielsen LL . 2000 Cancer Gene Ther. 7: 1469–1479

  • Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt M-T, Huang W-M, Johnson DE, Anderson SC, Wen SF, Bookstein R, Shepard HM, Gregory RJ . 1994 Hum. Gene Ther. 5: 1079–1088

  • Yaginuma Y, Westphal H . 1992 Cancer Res. 52: 4196–4199

Download references

Acknowledgements

We thank Dr Bruno Amati in DNAX Research Institute for helpful discussion, the critical reading of the manuscript, Dr Beth Hutchins in Canji Inc. for providing us rAd-p53 and rAd-control, Jeremy Shinoda in Canji Inc. for technical support, and Dr Maureen Murphy in Fox Chase Cancer Center for providing survivin expression plasmid and exchanging data prior to publication.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Suxing Liu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mirza, A., McGuirk, M., Hockenberry, T. et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21, 2613–2622 (2002). https://doi.org/10.1038/sj.onc.1205353

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205353

Keywords

This article is cited by

Search

Quick links